In a meta-analysis of 22 studies in patients with nonalcoholic fatty liver disease (NAFLD), weight loss interventions were associated with improvements in alanine aminotransferase level, liver steatosis, histologic NAFLD activity score, and
Infliximab may have been used inappropriately in Crohn's disease and underused in ulcerative colitis, according to the authors of an analysis of hospitalizations, intestinal resections, and drug costs related to inflammatory bowel disease (IBD).
Based on the results, study authors suggested expanding colorectal cancer (CRC) screening to patients 45 years of age, but an accompanying editorial expressed concern that the risks could outweigh the benefits in the general population.
An expert review from the American Gastroenterological Association cautioned against using opioids to treat pain from irritable bowel syndrome, functional dyspepsia, or centrally mediated abdominal pain syndrome, among other advice.
The guideline focuses on oral and topical 5-aminosalicylic acid medications, rectal corticosteroids, and oral budesonide in patients with mild to moderate disease.
Monotherapy for inflammatory bowel disease (IBD) with an immunosuppressive agent was associated with a lower risk of serious infection than a tumor necrosis factor (TNF) antagonist alone or an anti-TNF plus an immunosuppressive agent, according to a
In this Swedish case-control study, any previous GI infection and previous bacterial, parasitic, and viral GI infection were associated with higher risk for inflammatory bowel disease (IBD) versus controls.
The therapy should be considered in patients with genotype 1 infection who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load below 6,000,000 IU/mL, a study found.
A multitarget fecal immunochemical test (FIT) could reduce colorectal cancer incidence and death and might be cost-effective, according to a recent validation study.
Clarithromycin triple therapy should be used for first-line treatment of Helicobacter pylori infection only in patients with no history of macrolide exposure who live in areas where H. pylori resistance to clarithromycin is known to be low, among